Core Insights - Evaxion A/S has expanded its R&D pipeline with the introduction of EVX-04, an AI-designed precision cancer vaccine candidate targeting acute myeloid leukemia (AML) [1][10] - The vaccine is designed to target non-conventional ERV tumor antigens from the dark genome, which are present in tumors but absent in normal tissue, making them attractive for cancer vaccines [2][9] - EVX-04 aims to be an "off-the-shelf" vaccine, preproduced and ready for immediate administration after diagnosis, effective across a wide range of patients regardless of immune and tumor ERV antigen differences [4][5] Research and Development - The AI-Immunology™ platform has identified ERV antigens in patient tumor sequencing data and selects optimal fragments for effective vaccine targets [3][9] - New preclinical data shows that EVX-04 induces strong T-cell responses and kills cancer cells, with results to be presented at the American Society of Hematology (ASH) Annual Meeting on December 6, 2025 [6][10] - The presentation will include an abstract titled "Dark genome interrogation identifies novel antigens in acute myeloid leukemia – developing an off-the-shelf vaccine from machine learning to clinic" [8] Company Overview - Evaxion is a pioneering TechBio company utilizing its AI platform, AI-Immunology™, to develop novel immunotherapies for cancer and infectious diseases [12] - The company is committed to transforming patient outcomes by providing innovative and targeted treatment options [12]